Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma

Bone Marrow Transplantation

Volumn 39, Issue 7, 2007, Pages 389-396

  Schmidt Hieber, M ^a   Blau, I W ^a   Trenschel, R ^b   Andreesen, R ^c   Stuhler, G ^d   Einsele, H ^d   Kanz, L ^e   Keilholz, U ^a   Marinets, O ^a   Beelen, D W ^b   Fauser, A A ^f   Volin, L ^g   Ruutu, T ^g   Uharek, L ^a   Fietz, T ^h   Knauf, W ⁱ   Hopfenmuller W ^a   Thiel, E ^a   Freund, M ^j   Casper, J ^j  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f Klinik fur Knochenmarktransplantation und Hamatologie/Onkologie GmbH   (Germany)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h Onkologische Schwerpunkpraxis ^*  (Germany)

ⁱ Bethanien Krankenhaus Frankfurt   (Germany)

^j UNIVERSITY OF ROSTOCK   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THALIDOMIDE; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG FATALITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAFT FAILURE; HUMAN; INFECTION; MALE; MONOTHERAPY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; VEIN OCCLUSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 33947657465     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705605     Document Type: Article

References (47)

1. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991; 325: 1267-1273.
2. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208-215.
3. Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-1322.
4. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A el al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303.
5. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the chronic leukaemia working party of the EBMT. Blood 2005; 105: 4532-4539.
6. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367-373.
7. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924.
8. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362-4364.
9. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood 1996; 87: 1196-1198.
10. Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C, Monfardini S. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol 2004; 51: 171-189.
11. Schetelig J, Bornhauser M, Kiehl M, Schwerdtfeger R, Kroger N, Runde V et al. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation - a retrospective analysis. Bone Marrow Transplant 2004; 33: 483-490.
12. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
13. Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 1990; 17 (Suppl 8): 49-62.
14. Gahrton G. Progress in hematopoietic stem cell transplantation in multiple myeloma. Curr Opin Hematol 2005; 12: 463-470.
15. Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: Impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001; 19: 3340-3349.
16. Gropp M, Meier W, Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 1998; 71: 94-98.
17. Schmittel A, Scheulen ME, Bechrakis NE, Strumberg D, Baumgart J, Bornfeld N et al. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 2005; 15: 205-207.
18. Fichtner I, Becker M, Baumgart J. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 2003; 39: 801-807.
19. Meinhardt G, Dayyani F, Jahrsdorfer B, Baumgart J, Emmerich B, Schmidmaier R. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 2003; 122: 892-899.
20. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233-241.
21. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209-4216.
22. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U et al. Treosulfan and fludarabine: A new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725-731.
23. Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H et al. Treosulfan/ fludarabine: A new conditioning regimen in allogeneic transplantation. Ann Hematol 2004; 83 (Suppl 1): 70-71.
24. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant 2001; 28: 101-103.
25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
26. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215--233.
27. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
28. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
29. Valcarcel D, Martino R, Caballero D, Mateos MV, Perez-Simon JA, Canals C et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003; 31: 387-392.
30. Griskevicius L, Gaughan U, Cancparo R, Nilsson C, Hassan M. The myeloablative and immunosuppressive properties of treosulfan in mice. ASH Annual Meeting 2001. Orlando, USA, Abstract number 5022.
31. Westerhof GR, Ploemacher RE, Boudewijn A, Blokland I, Dillingh JH, McGown AT et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000; 60: 5470-5478.
32. Ploemacher RE, Westerhof GR, Blokland I, Baumgart J, Down JD. Treosulfan as an Alternative Conditioning Agent in Bone Marrow Transplantation. Bone Marrow Transplant 2000a; 25 (Suppl 1): 421.
33. Sjoo F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 2006; 34: 115-121.
34. Weissert R, Wiendl H, Pfrommer H, Storch MK, Schreiner B, Barth S et al. Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. J Neuroimmunol 2003; 144: 28-37.
35. Ploemacher RE, Johnson KW, Rombouts EJC, Etienne K, Westerhof GR, Baumgart J et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004; 10: 236-245.
36. Bornhauser M, Thiede C, Schuler U, Platzbecker U, Freiberg-Richter J, Helwig A et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000; 26: 119-125.
37. Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003; 31: 339-345.
38. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028.
39. Lamba R, Abella E, Kukuruga D, Klein J, Savasan S, Abidi MH et al. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia 2004; 18: 1681-1686.
40. Perez-Simon JA, Caballero D, Diez-Campelo M, Lopez-Perez R, Mateos G, Canizo C et al. Chimerism, and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423-1431.
41. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
42. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T et al. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
43. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216.
44. Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P Cavenagh J et al. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning-evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005; 128: 496-502.
45. Schetelig J, Kroger N, Held TK, Thiede C, Krusch A, Zabelina T et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002; 87: 299-305.
46. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
47. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.